Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 04, 2026 10:00 ET | Source: Dewpoint Therapeutics

Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer

Dewpoint doses first patient in Phase 1a/2a trial of DPTX3186, an FDA Fast Track, Orphan-designated beta-catenin modulator for advanced solid tumors.